<?xml version="1.0" encoding="UTF-8"?>
<p>In a prophylactic regimen of the use of passive immunotherapy in persons at risk, the aim is to prevent disease. Used therapeutically, the passive serum is administered to patients with clinical manifestations of the disease to reduce the severity of symptoms and mortality. The efficacy of these approaches cannot be measured without conducting a controlled clinical trial[
 <xref rid="B72" ref-type="bibr">72</xref>].
</p>
